scholarly journals Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis

BMJ ◽  
2012 ◽  
Vol 345 (nov05 1) ◽  
pp. e7097-e7097 ◽  
Author(s):  
L. H. Rasmussen ◽  
T. B. Larsen ◽  
T. Graungaard ◽  
F. Skjoth ◽  
G. Y. H. Lip
Keyword(s):  
Atrial Fibrillation ◽  
Secondary Prevention ◽  
Stroke Prevention ◽  
Oral Anticoagulant ◽  
Indirect Comparison ◽  
Comparison Analysis ◽  
Primary And Secondary Prevention ◽  
New Oral Anticoagulant ◽  
Anticoagulant Drugs

Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease

2016 ◽  
Vol 23 (19) ◽  
pp. 2055-2069 ◽  
Author(s):  
Tatjana S. Potpara ◽  
Vera Jokic ◽  
Nikolaos Dagres ◽  
Torben B. Larsen ◽  
Deirdre A. Lane ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vitamin K ◽  
Stroke Prevention ◽  
Oral Anticoagulant ◽  
Anticoagulant Drugs

scholarly journals NEW ORAL ANTICOAGULANT DRUGS IN ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROME

2013 ◽  
pp. 42-48
Author(s):  
Aleksandra Novaković ◽  
Tatjana Divac ◽  
Ivan Stojanović ◽  
Predrag Milojević ◽  
Dragoslav Nenezić
Keyword(s):  
Atrial Fibrillation ◽  
Acute Coronary Syndrome ◽  
Oral Anticoagulant ◽  
Coronary Syndrome ◽  
New Oral Anticoagulant ◽  
Anticoagulant Drugs

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation

2014 ◽  
Vol 111 (05) ◽  
pp. 981-988 ◽  
Author(s):  
Torben Larsen ◽  
Lars Rasmussen ◽  
Gregory Y. H. Lip ◽  
Flemming Skjøth
Keyword(s):  
Atrial Fibrillation ◽  
Gastrointestinal Bleeding ◽  
Ischaemic Stroke ◽  
Major Bleeding ◽  
Stroke Prevention ◽  
Dabigatran Etexilate ◽  
Indirect Comparison ◽  
High Dose ◽  
Efficacy And Safety ◽  
Comparison Analysis

SummaryLarge Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against each other. For high-dose edoxaban vs apixaban, there were no significant differences in efficacy endpoints, mortality, myocardial infarction and major bleeding. Apixaban was associated with less major or clinically relevant non-major bleeding (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.70–0.90) and gastrointestinal bleeding (HR 0.72; 95% CI 0.53–0.99). For dabigatran 110 mg twice daily, there were no significant differences in the main efficacy or safety endpoints. Dabigatran 150 mg bid was associated with lower stroke/systemic embolism (SE) (HR 0.75; 95% CI 0.56–0.99), stroke (HR 0.73; 95% CI 0.55–0.96) and haemorrhagic stroke (HR 0.48; 95% CI 0.23–0.99). There were no significant differences between high-dose edoxaban vs rivaroxaban for efficacy endpoints or mortality, but rivaroxaban had more major and/or clinically relevant non-major bleeding. When compared to low-dose edoxaban, apixaban was associated with lower stroke/SE (HR 0.70; 95% CI 0.55–0.89), stroke (HR 0.70; 95% CI 0.55–0.92) and ischaemic stroke (HR 0.65; 95% CI 0.50–0.89), but more major bleeding (HR 1.47; 95% CI 1.20–1.80). For dabigatran 110 mg bid, there were no significant differences in the efficacy endpoints, but dabigatran 110 mg bid had higher major (and gastrointestinal) bleeding. Dabigatran 150 mg bid and rivaroxaban were associated with lower stroke/SE and ischaemic stroke, but higher bleeding rates. In the present analysis, we have provided for the first time, comparisons of efficacy and safety of edoxaban against other NOACs. Notwithstanding the significant limitations of an indirect comparison analysis, some differential effects are evident with the NOACs for stroke prevention, allowing us to allow the prescriber a ‘choice’ to be able to fit the drug to the patient clinical profile (and vice versa).Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief.

scholarly journals Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions

Thrombosis ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Jorge Ferreira ◽  
Daniel Ferreira ◽  
Miguel Viana-Baptista ◽  
Paulo Bettencourt ◽  
Rui Cernadas ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Real World ◽  
Stroke Prevention ◽  
Oral Anticoagulant ◽  
Dabigatran Etexilate ◽  
Direct Thrombin Inhibitor ◽  
Thrombin Inhibitor ◽  
Joint Effort ◽  
Nonvalvular Atrial Fibrillation ◽  
New Oral Anticoagulant

Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is the joint effort of a panel of experts from different specialties and provides information on the use of dabigatran, in anticipation of the challenges that will come with increased usage.

Sign in / Sign up

Export Citation Format

Share Document